Quick Facts

• Addresses: Temporary reduction of cough frequency.
• Common Use: Relieves cough associated with the common cold or flu.
• Relief Scope: Helps diminish the impulse to cough.

---

What Туссикод Treats: Main Uses and Benefits

Туссикод, which often contains the active ingredient dextromethorphan, is utilized to provide temporary relief from the presence of cough. The medication is part of the class of agents known as antitussives, which serve to help manage the frequency of coughing episodes.

Its therapeutic domain includes cough that is related to minor irritation of the throat and bronchial tubes, which may accompany the common cold or seasonal influenza (the flu). The intended effect is to assist in reducing the urge to cough, supporting patient comfort. It is important to note that this product is designed to offer symptom relief and does not address the underlying cause of the cough or accelerate recovery from the illness.

This medication is widely available without a prescription.

The eligibility to use Butamirate citrate (Туссикод) is strictly defined by regulatory documentation across several specific population groups.

Absolute Contraindications

The medicine is prohibited for children under 3 years of age and for women in the first trimester of pregnancy. Use is also strictly contraindicated for any patient with known hypersensitivity to the active ingredient or its excipients, as well as for those with rare hereditary conditions such as fructose intolerance.

Age and Conditional Use

Use is established for Adults and Adolescents (typically over 12 years). However, some formulations are not recommended for children under 6 years of age. Caution is required for patients with impaired renal or hepatic function, as regulatory data on drug accumulation in these specific groups is lacking.

Physiological State Restrictions

The product is not recommended for use during breastfeeding due to insufficient data on drug excretion. In the second and third trimesters of pregnancy, use is conditional and should only occur if the treating physician determines it is absolutely necessary. Furthermore, regulatory warnings state that concomitant use with expectorants must be avoided.

Interactions with other medicines and products

The interaction profile for Butamirate citrate is structured around restrictions concerning specific co-administered medicine classes and conditions affecting drug clearance, as documented in official government sources.

---

Pharmacodynamic and Timing Restrictions

Expectorants and Mucolytics must be avoided. This is a mandatory avoidance rule documented in regulatory summaries because the antitussive effect of butamirate suppresses the cough reflex, directly opposing the action of expectorants. This pharmacodynamic conflict can lead to the stagnation and accumulation of mucus in the respiratory tract, which increases the documented risk of bronchospasm and subsequent respiratory tract infections.

---

Pharmacokinetic Modification Risks

Co-administration with Strong Enzyme Inhibitors is officially cautioned against. This pharmacokinetic interaction poses a risk of increased systemic exposure of butamirate, potentially leading to higher plasma concentrations. Similarly, butamirate should not be used together with medicinal products that have a narrow therapeutic index due to the possible risk of altered exposure to these sensitive co-administered agents.

---

Clearance-Impairment Note

Official regulatory information includes a note concerning populations with compromised drug elimination pathways. Patients with renal and/or liver disease may be at greater risk because of the potential for butamirate and its metabolites to accumulate due to impaired clearance. The medicine may be taken with or without food.

Central Modulation of the Cough Reflex

Туссикод primarily exerts its action within the brainstem by engaging and modulating key molecular targets in the central nervous system (CNS). The active components interact with Sigma-1 (sigma1) and NMDA receptors in the medulla oblongata, the region housing the cough control center. This mechanism involves sigma1 receptor agonism and NMDA receptor non-competitive antagonism, which together reduce the intrinsic excitability of the local neural network.

Pathway Interference and Physiological Consequence

This activity is coupled with modulation of central neurotransmitter systems, specifically interfering with glutamate, serotonin, and norepinephrine signaling. By altering the signaling dynamics of the cough pathway and reducing excitability, the drug modifies the subsequent neural cascade. The systemic physiological consequence of this central action is the elevation of the cough threshold, reducing the frequency and intensity of efferent signals transmitted to the respiratory musculature. Furthermore, the drug's full receptor-blocking potential is contingent upon its bio-activation by metabolic enzymes, notably CYP2D6, which converts the parent compound into its active metabolite.

The administration of Butamirate citrate is restricted to the oral route, utilizing dosage forms such as syrup (7.5 mg/5 mL) and 50 mg sustained-release (SR) tablets. Dosage is dependent on the patient's age and the selected formulation. The syrup is measured using a dosing device to ensure administration of the intended amount.

Official Dosing Schedules

Age Group	Formulation	Standard Dose & Frequency
Adults	SR Tablet (50 mg)	1 tablet, 2 to 3 times daily
Adults	Syrup	15 mL, 3 to 4 times daily
Children 4-6 yrs	Syrup	5 mL, 3 times daily

The medication is intended for a short-term symptomatic course. Treatment is typically limited to a period of four to five days, after which professional medical evaluation is required if the condition persists. An administration constraint involves avoiding concomitant use with expectorant medicines. If a dose is missed, the standard procedure is to skip the missed dose and resume the normal dosing schedule; the dose is not doubled. The syrup formulation is generally not recommended for children under 4 years of age.

Research Evidence / Overview of Studies for Туссикод

---

Evidence for Use in Acute Cough

Research has explored Tussicod in study scenarios involving conditions associated with acute or disruptive episodes, such as those caused by a cold or upper respiratory infection. Studies exploring short-term symptom changes typically involve short-term Randomized Controlled Trials (RCTs) where participants were observed for a few days up to one week. Researchers were specifically monitoring outcomes describing episodic or acute changes, such as the patient-reported frequency and severity of their coughing, and how often coughing occurred at night.

Findings describe patterns observed in the studies. Studies reported how symptoms evolved in the observed populations, which included patient-reported outcomes describing perceived discomfort related to coughing. However, findings were mixed across various studies, and evidence quality varies across studies. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

---

Comparison Studies: Placebo and Standard Options

Tussicod was evaluated in studies that compared it to an inactive substance (placebo) and explored comparisons to other available cough treatments. These comparison trials were used in research exploring how symptoms change over time when Tussicod is used versus when a placebo or another drug is used. The research was evaluated in study scenarios where the drug was used.

Studies report how symptoms evolved in the observed populations when Tussicod was compared directly to a placebo. Comparisons to other standard cough treatments were explored and described. Research contributes to describing short-term changes observed in these controlled settings, but results apply only to the populations studied.

---

Research Gaps and What Remains Uncertain About Туссикод

Research highlights what is known — and what is still uncertain — about Tussicod. One major limitation is that the sample sizes were modest in many individual trials, and the evidence quality varies across studies, sometimes making the overall picture unclear. Furthermore, there is limited information for long-term outcomes or how the drug might perform in conditions characterized by fluctuating or episodic manifestations over a long period. Certainty remains low in several key areas of the research landscape, and further research is ongoing to address these evidence gaps.

Common questions about Туссикод (FAQ)

Q: How quickly does the effect of Туссикод usually start?

According to official product information, the active ingredient is rapidly absorbed into the body. Evidence indicates that the onset of effect typically begins approximately 30 minutes after the first dose is taken.

Q: How long does the effect of one dose of Туссикод last?

The sustained-release formulation is specifically manufactured to provide a prolonged effect. Official documents state that this design allows the medication to maintain its action for up to 12 hours.

Q: Do any foods or drinks need to be avoided while taking Туссикод?

Official warnings advise against consuming alcohol while taking this medicine, as this combination may potentially worsen a patient's existing condition. The medication itself may be taken with or without food.

Q: Can I take Туссикод if I am already taking pain relievers?

Official documents note that the use of strong enzyme inhibitors or medicines with a narrow therapeutic index can potentially alter the body’s exposure to butamirate. This information is relevant, as certain types of pain relievers may fall into these categories.

Q: Can elderly people use Туссикод safely?

Official dosing schedules are provided for adults, but specific restrictions based solely on advanced age are generally not stated in regulatory documents. Official guidance highlights the need for caution for any patient with impaired kidney (renal) or liver (hepatic) function, as this may lead to drug accumulation.

Q: Does the time of day I take Туссикод make a difference?

The Sustained-Release (SR) tablet formulation is designed to be taken at specific time intervals multiple times daily. This schedule aims to maintain a consistent concentration of the active ingredient by keeping the intervals between doses at a set number of hours.

Q: Why do official documents mention combining Туссикод with alcohol as a concern?

Official warnings advise against alcohol consumption because it may potentially worsen the patient's existing health condition. Additionally, alcohol may increase the effects of the medication that can cause dizziness and drowsiness.

Q: Why do some people experience mild headaches with Туссикод?

Headache is listed as a potential adverse reaction in regulatory documentation. While all officially documented side effects are considered rare, headache is sometimes reported as a less common effect.

Q: Can Туссикод make existing dry mouth symptoms worse?

Dry mouth is included in the list of potential adverse reactions found in regulatory documentation. Although all officially documented side effects are considered rare, dry mouth is a recognized possibility.

Q: Is it necessary to finish the entire course of Туссикод as described in the instructions?

The medicine is intended for a short-term symptomatic course, meaning it is used only to relieve symptoms while they persist. Regulatory instructions indicate that treatment is to be stopped if the cough resolves. If the cough persists beyond four to five days of use, official guidelines note that professional medical evaluation is required.

Q: If I stop taking Туссикод suddenly, will I experience any withdrawal effects?

The drug is classified as a non-narcotic antitussive, meaning it is chemically distinct from substances that carry a risk of dependence. Regulatory documents do not contain warnings about withdrawal effects following cessation of use.

Q: Can I take Туссикод with herbal supplements?

Regulatory documents list a caution against medicines that act as strong enzyme inhibitors. Because some herbal supplements can affect the same enzymes involved in the body's processing of medicines, this information highlights the need to verify for any concurrent use.

Q: Do official documents mention any potential for dependence with Туссикод?

Official product information classifies the drug as a non-narcotic antitussive. This classification distinguishes it from controlled substances; regulatory documents do not contain warnings about dependence.

Q: How can I tell if a side effect I'm experiencing is serious?

Official patient information describes that immediate medical attention is necessary if signs such as skin rashes, stomach or intestinal bleeding, or signs of hypersensitivity (an allergic-type response) develop. The label instructs stopping the medicine in these cases.

Q: Does the drug have any known interactions with birth control pills?

Official warnings exist against co-administration with medicinal products that are strong enzyme inhibitors. This assessment requires information from a healthcare professional, as official documents focus on the effect of strong enzyme inhibitors.

Q: Why is hydration often mentioned alongside taking Туссикод?

Some non-drug advice included in patient information suggests drinking plenty of fluids while ill. This is generally recommended to help keep the throat moist and can help loosen any mucus in the airways.

Q: Is the main ingredient in Туссикод found in other popular medicines?

The active ingredient in this medication is Butamirate citrate. Official information confirms that this substance is available internationally under various brand names.

Q: Why is it generally recommended to consult a doctor before using Туссикод if I have asthma?

Official patient information often includes a request to inform a healthcare provider of any history of chronic lung conditions before using the medicine. This may include conditions like asthma or emphysema.

Q: What are the known potential interactions with anti-depressant medications?

The official documentation cautions against strong enzyme inhibitors, which include some anti-depressants. The drug's action relies on an enzyme called CYP2D6 for bio-activation, making the assessment of potential interactions a necessary step for a healthcare professional.

Q: Does Туссикод contain common allergens like gluten or lactose?

Official documentation does not universally confirm or deny the presence of specific common allergens like gluten or lactose. The medicine is contraindicated for those with fructose intolerance, and all inactive ingredients are listed in the Patient Information Leaflet (PIL) for the specific product formulation.

Q: If I have a food allergy, is there a risk with the inactive ingredients in Туссикод?

The drug is strictly contraindicated for anyone with a known hypersensitivity to the active substance or any of the inactive ingredients (excipients). This information is listed in the Patient Information Leaflet (PIL), which is the source for verifying against known allergies.

Storage Requirements

Official labeling for Butamirate citrate oral solutions requires the product be stored at a temperature not exceeding 25 C. The container must be kept tightly closed in a cool and dry place, protected from moisture and heat, to maintain its stability. All medicine must be kept out of the sight and reach of children to prevent accidental ingestion.

Stability and Disposal

The syrup formulation has an in-use shelf life of 6 months after the bottle is first opened, and it must not be used past the expiration date on the packaging. Unused or expired Туссикод must not be thrown away via wastewater or household waste. Disposal should be managed by asking a pharmacist for advice on pharmaceutical waste disposal, in accordance with local environmental regulations.